Brain Characterization of Amyloid Protein and Glucose Metabolism of ALFA Project Participa
Study to understand factors related with the preclinical stages of Alzheimer's Disease and investigate markers that predict its progression. Cross-sectional and single arm study performed on a subgroup of individuals recruited in the ALFA project. Study without therapeutic interest for the research participants (440 pa
| Condition(s) | Alzheimer's Disease |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | Study to understand factors related with the preclinical stages of Alzheimer's Disease and investigate markers that predict its progression. Cross-sectional and single arm study performed on a subgroup of individuals recruited in the ALFA project. Study without therapeutic interest for the research participants (440 participants of the ALFA project who have been selected for being cognitively healthy and in their vast majority are direct descendants of patients diagnosed with Alzheimer's Disease). Each study candidate will be selected from the ALFA project (STUDY 45-65 FPM/2012) according to their clinical characteristics, their compliance to selection criteria and their desire to participate in this study. After signing this study's specific informed consent form, the neuropsychological s |
| Who can participate | Inclusion Criteria: * To sign the study informed consent form approved by the corresponding authorities. * Men and women enrolled in the ALFA project (STUDY 45-65 FPM/2012). * Participants with a cerebral MRI (magnetic resonance imaging) not suggestive of radiological incidental findings constituting an exclusion criterion. * Cognition within psychometrically normal ranges: MMSE (Mini Mental State Examination ≥26 and Semantic Fluency (animals) ≥12. * Score of 0 in the CDR scale (Clinical Dementia Rating). * Good knowledge of the language and being literate. * Female participants should be post-menopausal or present a negative pregnancy test at the moment of PET acquisition. Exclusion Criteria: * Present cognitive impairment. * Presence of clinically relevant psychiatric disorder according |
| Ages | 45 Years to 75 Years |
| Sex | All |
| Accepts healthy volunteers | Yes |
| Lead sponsor | Barcelonabeta Brain Research Center, Pasqual Maragall Foundation |
| Locations | Barcelona, Catalonia, Spain |
| Start date | 2017-03-01 |
| NCT ID | NCT02685969 |
| Official listing | https://clinicaltrials.gov/study/NCT02685969 |